Outcome assessment for clinical dementia trials could be enhanced by using the Mini-mental State Examination (MMSE) and the Hopkins Verbal Learning Test (HVLT), in addition to imaging and genetic screening. The statistical power of trials could be increased if heterogeneity of the sample were reduced by the administration of a risk factor inventory which could be used for subject selection or selection of drug responders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/S1041610207005169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Narrative Review on the Neuroprotective Potential of Brown Macroalgae in Alzheimer's Disease.
Nutrients
December 2024
Foodomics Lab, Institute of Food Science Research (CIAL, CSIC), 28049 Madrid, Spain.
Systematic Alzheimer's disease (AD) is a neurodegenerative disease increasingly prevalent in the aging population. AD is characterized by pathological features such as -amyloid (A) plaque accumulation, tau neurofibrillary tangles formation, oxidative stress, an impaired cholinergic system, and neuroinflammation. Many therapeutic drugs have been developed to slow the progression of AD by targeting these pathological mechanisms.
View Article and Find Full Text PDFPromotes Antioxidant Gene Expression and Mitochondrial Oxidative Respiration in Experimental Autoimmune Encephalomyelitis.
Pharmaceuticals (Basel)
December 2024
Department of Neurology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
(L.) Urban (family Apiaceae) () is a traditional botanical medicine used in aging and dementia. Water extracts of (CAW) have been used to treat neuropsychiatric symptoms in related animal models and are associated with increases in antioxidant response element (ARE) genes and improvements in mitochondrial respiratory function and neuronal health.
View Article and Find Full Text PDFUnderstanding the Molecular Impact of Physical Exercise on Alzheimer's Disease.
Int J Mol Sci
December 2024
Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, Spain.
Alzheimer's disease is one of the most common neurodegenerative diseases, characterized by a wide range of neurological symptoms that begin with personality changes and psychiatric symptoms, progress to mild cognitive impairment, and eventually lead to dementia. Physical exercise is part of the non-pharmacological treatments used in Alzheimer's disease, as it has been shown to delay the neurodegenerative process by improving the redox state in brain tissue, providing anti-inflammatory effects or stimulating the release of the brain-derived neurotrophic factor that enhances the brain structure and cognitive performance. Here, we reviewed the results obtained from studies conducted in both animal models and human subjects to comprehend how physical exercise interventions can exert changes in the molecular mechanisms underlying the pathophysiological processes in Alzheimer's disease: amyloid β-peptide pathology, tau pathology, neuroglial changes, mitochondrial dysfunction, and oxidative stress.
View Article and Find Full Text PDFIrisin: A Multifaceted Hormone Bridging Exercise and Disease Pathophysiology.
Int J Mol Sci
December 2024
IRCSS Santa Lucia Foundation, European Center for Brain Research, 00143 Rome, Italy.
The fibronectin domain-containing protein 5 (FNDC5), or irisin, is an adipo-myokine hormone produced during exercise, which shows therapeutic potential for conditions like metabolic disorders, osteoporosis, sarcopenia, obesity, type 2 diabetes, and neurodegenerative diseases, including Alzheimer's disease (AD). This review explores its potential across various pathophysiological processes that are often considered independent. Elevated in healthy states but reduced in diseases, irisin improves muscle-adipose communication, insulin sensitivity, and metabolic balance by enhancing mitochondrial function and reducing oxidative stress.
View Article and Find Full Text PDFThe Promising Potency of Sodium-Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients.
Biomedicines
December 2024
Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Type 2 diabetes mellitus (T2DM), accounting for the majority of diabetes mellitus prevalence, is associated with an increased risk of cognition decline and deterioration of cognition function in diabetic patients. The sodium-glucose cotransporter 2 (SGLT2), located in the renal proximal tubule, plays a role in urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac and renal improvement in preventing and treating cognitive impairment (CI), including mild cognitive impairment, Alzheimer's disease and vascular dementia in T2DM patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!